‘Wild West’ peptide craze surges beyond GLP-1s as FDA faces pressure to ease access

The peptide market is experiencing rapid growth as GLP-1 weight-loss medications gain popularity, with largely unregulated peptides being sold through compounding pharmacies and unverified vendors. The FDA is evaluating whether to loosen regulations on several peptides, while compounding pharmacies have expanded to meet demand and offer dosing flexibility that commercial products cannot provide.